Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Promising emerging therapies for AML and the challenges that remain

In this video, Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, shares his views on promising therapeutic approaches for the treatment of elderly and transplant-ineligible patients with acute myeloid leukemia (AML), highlighting the potential for triplet regimens which involve the addition of an agent to the azacitidine and venetoclax standard of care. Prof. Vyas also highlights the potential for using measurable residual disease (MRD) and the challenges associated with using immunotherapy in AML. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Jazz: Honoraria; Astellas: Honoraria; Abbvie: Consultancy, Honoraria; Pfizer: Honoraria; Gilead: Honoraria; BMS: Research Funding; Auron Therapeutics: Current holder of stock options in a privately-held company.